Aaron Mitchell
@thewonkologist.bsky.social
Medical oncologist and health services researcher. Focusing on health care costs, physician-industry COI, and oncology reimbursement reform. Opinions mine.
It had been far too long since my last GREETINGS OF THE DAY email! This one may be my new all time favorite.
How much better could you signal "this is spam"? LOL right now 🤣
@ankurfactorial.bsky.social
How much better could you signal "this is spam"? LOL right now 🤣
@ankurfactorial.bsky.social
November 14, 2025 at 6:50 PM
It had been far too long since my last GREETINGS OF THE DAY email! This one may be my new all time favorite.
How much better could you signal "this is spam"? LOL right now 🤣
@ankurfactorial.bsky.social
How much better could you signal "this is spam"? LOL right now 🤣
@ankurfactorial.bsky.social
Postdoc opportunity at @mskcancercenter.bsky.social ! Read about and apply to OPTICS below:
November 8, 2025 at 4:15 PM
Postdoc opportunity at @mskcancercenter.bsky.social ! Read about and apply to OPTICS below:
Huge thanks to the large, multidisciplinary team that helped get this study to the finish line!
I joke that I've been planning this study since I started oncology fellowship - now 10 years ago - but this is very true. @ethanbasch.bsky.social
7/
I joke that I've been planning this study since I started oncology fellowship - now 10 years ago - but this is very true. @ethanbasch.bsky.social
7/
November 5, 2025 at 5:33 PM
Huge thanks to the large, multidisciplinary team that helped get this study to the finish line!
I joke that I've been planning this study since I started oncology fellowship - now 10 years ago - but this is very true. @ethanbasch.bsky.social
7/
I joke that I've been planning this study since I started oncology fellowship - now 10 years ago - but this is very true. @ethanbasch.bsky.social
7/
However, the result for profit margin was very null.
All cancer types clustered around that red line of OR=1 (no difference)
5/
All cancer types clustered around that red line of OR=1 (no difference)
5/
November 5, 2025 at 5:33 PM
However, the result for profit margin was very null.
All cancer types clustered around that red line of OR=1 (no difference)
5/
All cancer types clustered around that red line of OR=1 (no difference)
5/
For clinical benefit, the result was clearly positive. More beneficial (per NCCN) treatments were used more often.
OR = 1.62 in our random effects meta-analysis.
4/
OR = 1.62 in our random effects meta-analysis.
4/
November 5, 2025 at 5:33 PM
For clinical benefit, the result was clearly positive. More beneficial (per NCCN) treatments were used more often.
OR = 1.62 in our random effects meta-analysis.
4/
OR = 1.62 in our random effects meta-analysis.
4/
But, when we looked at appropriate use in CRPC, there was more variation. Across 3 networks (each a different color), 2 initiated bone agents for most patients. But 1 network lagged, initiating bone agents for only a minority of patients.
3/
3/
November 4, 2025 at 3:39 AM
But, when we looked at appropriate use in CRPC, there was more variation. Across 3 networks (each a different color), 2 initiated bone agents for most patients. But 1 network lagged, initiating bone agents for only a minority of patients.
3/
3/
Great review by @amitabhchandra.bsky.social and Mark Shepard in @nejm.org on the challenges of corporatization in US healthcare
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
September 1, 2025 at 5:12 PM
Great review by @amitabhchandra.bsky.social and Mark Shepard in @nejm.org on the challenges of corporatization in US healthcare
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
In at least 1 case, the answer seems to be that the company is still pursuing additional approvals.
This drug is belantamab mafodotin (Blenrep).
Notably, Blenrep was also one of the most heavily-promoted drugs on social media, which we also recently studied.
jamanetwork.com/journals/jam...
4/
This drug is belantamab mafodotin (Blenrep).
Notably, Blenrep was also one of the most heavily-promoted drugs on social media, which we also recently studied.
jamanetwork.com/journals/jam...
4/
August 28, 2025 at 1:13 AM
In at least 1 case, the answer seems to be that the company is still pursuing additional approvals.
This drug is belantamab mafodotin (Blenrep).
Notably, Blenrep was also one of the most heavily-promoted drugs on social media, which we also recently studied.
jamanetwork.com/journals/jam...
4/
This drug is belantamab mafodotin (Blenrep).
Notably, Blenrep was also one of the most heavily-promoted drugs on social media, which we also recently studied.
jamanetwork.com/journals/jam...
4/
*SIGH*
Might as well unsubscribe at this point, am I right?
Might as well unsubscribe at this point, am I right?
August 22, 2025 at 7:33 PM
*SIGH*
Might as well unsubscribe at this point, am I right?
Might as well unsubscribe at this point, am I right?
The only place industry COI does *not* pervade medicine, it would seem, is on vaccine advisory panels!
New in @jama.com today, great work by @profgenkanter.bsky.social
cc @mdaware.org @by-cjewett.bsky.social @charlesornstein.bsky.social @joho.bsky.social
jamanetwork.com/journals/jam...
New in @jama.com today, great work by @profgenkanter.bsky.social
cc @mdaware.org @by-cjewett.bsky.social @charlesornstein.bsky.social @joho.bsky.social
jamanetwork.com/journals/jam...
August 18, 2025 at 10:46 PM
The only place industry COI does *not* pervade medicine, it would seem, is on vaccine advisory panels!
New in @jama.com today, great work by @profgenkanter.bsky.social
cc @mdaware.org @by-cjewett.bsky.social @charlesornstein.bsky.social @joho.bsky.social
jamanetwork.com/journals/jam...
New in @jama.com today, great work by @profgenkanter.bsky.social
cc @mdaware.org @by-cjewett.bsky.social @charlesornstein.bsky.social @joho.bsky.social
jamanetwork.com/journals/jam...
Credit where it’s due, Lander was the only competent bagel-orderer of the bunch
June 25, 2025 at 3:30 AM
Credit where it’s due, Lander was the only competent bagel-orderer of the bunch
I’m not endorsing Brad Lander, but the difference in bagel ordering competence is striking
June 21, 2025 at 5:07 PM
I’m not endorsing Brad Lander, but the difference in bagel ordering competence is striking
June 21, 2025 at 5:03 PM
The NYTimes should really consider upgrading their search function technology to 1998 AltaVista
June 14, 2025 at 11:24 PM
The NYTimes should really consider upgrading their search function technology to 1998 AltaVista
I’m all for reducing plastic.
But as an epidemiologist, I recognize this as a very strong counterfactual claim.
@epidbydesign.bsky.social have you ever considered teaching with this example?
But as an epidemiologist, I recognize this as a very strong counterfactual claim.
@epidbydesign.bsky.social have you ever considered teaching with this example?
June 3, 2025 at 2:27 PM
I’m all for reducing plastic.
But as an epidemiologist, I recognize this as a very strong counterfactual claim.
@epidbydesign.bsky.social have you ever considered teaching with this example?
But as an epidemiologist, I recognize this as a very strong counterfactual claim.
@epidbydesign.bsky.social have you ever considered teaching with this example?
Ok this is my favorite #ASCO25 poster thus far.
We oncologists both
1) beat GPT4 by a wide margin
2) pass the Turing test
I literally lol’ed at the examples in the bottom left. So obvious who is who - only a human doc knows to factor an insurance denial into their recs! 😂
We oncologists both
1) beat GPT4 by a wide margin
2) pass the Turing test
I literally lol’ed at the examples in the bottom left. So obvious who is who - only a human doc knows to factor an insurance denial into their recs! 😂
June 1, 2025 at 5:19 PM
Ok this is my favorite #ASCO25 poster thus far.
We oncologists both
1) beat GPT4 by a wide margin
2) pass the Turing test
I literally lol’ed at the examples in the bottom left. So obvious who is who - only a human doc knows to factor an insurance denial into their recs! 😂
We oncologists both
1) beat GPT4 by a wide margin
2) pass the Turing test
I literally lol’ed at the examples in the bottom left. So obvious who is who - only a human doc knows to factor an insurance denial into their recs! 😂
Presenting at #ASCO25 today!
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
May 31, 2025 at 9:25 PM
Presenting at #ASCO25 today!
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
🚨🚨🚨
Presenting our new study on Medicare Advantage at #ASCO25! Lower use of low value cancer care among Medicare Advantage beneficiaries.
Simultaneously published in JCO
👇🏼👇🏼👇🏼
ascopubs.org/doi/10.1200/...
Presenting our new study on Medicare Advantage at #ASCO25! Lower use of low value cancer care among Medicare Advantage beneficiaries.
Simultaneously published in JCO
👇🏼👇🏼👇🏼
ascopubs.org/doi/10.1200/...
May 31, 2025 at 8:49 PM
🚨🚨🚨
Presenting our new study on Medicare Advantage at #ASCO25! Lower use of low value cancer care among Medicare Advantage beneficiaries.
Simultaneously published in JCO
👇🏼👇🏼👇🏼
ascopubs.org/doi/10.1200/...
Presenting our new study on Medicare Advantage at #ASCO25! Lower use of low value cancer care among Medicare Advantage beneficiaries.
Simultaneously published in JCO
👇🏼👇🏼👇🏼
ascopubs.org/doi/10.1200/...
What this great @nytimes.com story highlights about overpriced bandages, reminds me quite a bit of the chemotherapy markups that cancer care providers keep
@bykatiethomas.bsky.social @sangerkatz.bsky.social
@bykatiethomas.bsky.social @sangerkatz.bsky.social
April 13, 2025 at 2:29 PM
What this great @nytimes.com story highlights about overpriced bandages, reminds me quite a bit of the chemotherapy markups that cancer care providers keep
@bykatiethomas.bsky.social @sangerkatz.bsky.social
@bykatiethomas.bsky.social @sangerkatz.bsky.social
I was today years old when I learned that the president of Nintendo of America is for real named Bowser
April 10, 2025 at 9:00 PM
I was today years old when I learned that the president of Nintendo of America is for real named Bowser
Searching online forums with the same question, I stumbled upon my soul mate.
March 12, 2025 at 5:37 PM
Searching online forums with the same question, I stumbled upon my soul mate.